无症状重度主动脉瓣狭窄合并心肌纤维化患者的早期干预:EVOLVED随机临床试验
该前瞻性、随机、开放标签、终点设盲试验在英国和澳大利亚24个心脏中心纳入224例无症状重度主动脉瓣狭窄合并心肌纤维化患者,比较早期瓣膜干预与指南导向保守管理。主要终点(全因死亡或非计划主动脉瓣狭窄相关住院)早期干预组18% vs 保守组23%(HR 0.79,95%CI 0.44-1.43,P=0.44),无显著差异;早期干预组12个月NYHA II-IV级症状比例更低(19.7% vs 37.9%,OR 0.37,95%CI 0.20-0.70)。
要点
- 早期瓣膜干预未显著降低全因死亡或非计划主动脉瓣狭窄相关住院(HR 0.79,95%CI 0.44-1.43,P=0.44)。
- 早期干预组非计划主动脉瓣狭窄住院低于保守组(6% vs 17%,HR 0.37,95%CI 0.16-0.88)。
- 早期干预组12个月NYHA II-IV级症状比例低于保守组(19.7% vs 37.9%,OR 0.37,95%CI 0.20-0.70)。
核心结论
- 在无症状重度主动脉瓣狭窄合并心肌纤维化患者中,早期主动脉瓣干预对全因死亡或非计划主动脉瓣狭窄相关住院无可见效果。
- 该试验主要终点95%CI较宽,需进一步研究确认这些发现。
研究设计与样本
- 前瞻性、随机、开放标签、终点设盲试验,2017年8月至2022年在英国和澳大利亚24个心脏中心开展。
- 纳入无症状重度主动脉瓣狭窄合并心肌纤维化患者,最终随访日期为2024年7月26日。
- 计划样本量356例,实际纳入224例 eligible 患者(平均[SD]年龄73[9]岁;女性63例[28%];平均[SD]主动脉瓣峰值流速4.3[0.5] m/s)。
- 干预为早期瓣膜干预(经导管或外科主动脉瓣置换)或指南导向保守管理。
主要发现
- 主要终点(全因死亡或非计划主动脉瓣狭窄相关住院)早期干预组113例中20例(18%)vs 指南导向保守管理组111例中25例(23%)(HR 0.79,95%CI 0.44-1.43;P=0.44;组间差异-4.82%,95%CI -15.31%至5.66%)。
- 9个预设次要终点中7个无显著差异。
- 全因死亡早期干预组113例中16例(14%)vs 保守组111例中14例(13%)(HR 1.22,95%CI 0.59-2.51)。
- 非计划主动脉瓣狭窄住院早期干预组113例中7例(6%)vs 保守组111例中19例(17%)(HR 0.37,95%CI 0.16-0.88)。
- 12个月NYHA II-IV级症状早期干预组21例(19.7%)vs 保守组39例(37.9%)(OR 0.37,95%CI 0.20-0.70)。
关键数值与推荐
- 主要终点HR 0.79(95%CI 0.44-1.43;P=0.44),组间差异-4.82%(95%CI -15.31%至5.66%)。
- 全因死亡HR 1.22(95%CI 0.59-2.51)。
- 非计划主动脉瓣狭窄住院HR 0.37(95%CI 0.16-0.88)。
- 12个月NYHA II-IV级症状OR 0.37(95%CI 0.20-0.70)。
局限性
- 实际纳入224例,低于原计划样本量356例。
- 主要终点95%CI较宽。
- 需进一步研究确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Development of myocardial fibrosis in patients with aortic stenosis precedes left ventricular decompensation and is associated with an adverse long-term prognosis. OBJECTIVE: To investigate whether early valve intervention reduced the incidence of all-cause death or unplanned aortic stenosis-related hospitalization in asymptomatic patients with severe aortic stenosis and myocardial fibrosis. DESIGN, SETTING, AND PARTICIPANTS: This prospective, randomized, open-label, masked end point trial was conducted between August 2017 and October 2022 at 24 cardiac centers across the UK and Australia. Asymptomatic patients with severe aortic stenosis and myocardial fibrosis were included. The final date of follow-up was July 26, 2024. INTERVENTION: Early valve intervention with transcatheter or surgical aortic valve replacement or guideline-directed conservative management. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause death or unplanned aortic stenosis-related hospitalization in a time-to-first-event intention-to-treat analysis. There were 9 secondary outcomes, including the components of the primary outcome and symptom status at 12 months. RESULTS: The trial enrolled 224 eligible patients (mean [SD] age, 73 [9] years; 63 women [28%]; mean [SD] aortic valve peak velocity of 4.3 [0.5] m/s) of the originally planned sample size of 356 patients. The primary end point occurred in 20 of 113 patients (18%) in the early intervention group and 25 of 111 patients (23%) in the guideline-directed conservative management group (hazard ratio, 0.79 [95% CI, 0.44-1.43]; P = .44; between-group difference, -4.82% [95% CI, -15.31% to 5.66%]). Of 9 prespecified secondary end points, 7 showed no significant difference. All-cause death occurred in 16 of 113 patients (14%) in the early intervention group and 14 of 111 (13%) in the guideline-directed group (hazard ratio, 1.22 [95% CI, 0.59-2.51]) and unplanned aortic stenosis hospitalization occurred in 7 of 113 patients (6%) and 19 of 111 patients (17%), respectively (hazard ratio, 0.37 [95% CI, 0.16-0.88]). Early intervention was associated with a lower 12-month rate of New York Heart Association class II-IV symptoms than guideline-directed conservative management (21 [19.7%] vs 39 [37.9%]; odds ratio, 0.37 [95% CI, 0.20-0.70]). CONCLUSIONS AND RELEVANCE: In asymptomatic patients with severe aortic stenosis and myocardial fibrosis, early aortic valve intervention had no demonstrable effect on all-cause death or unplanned aortic stenosis-related hospitalization. The trial had a wide 95% CI around the primary end point, with further research needed to confirm these findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03094143.
引用
- Loganath K, Craig NJ, Everett RJ, et al. Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial. JAMA. 2025. PMID: 39466640. doi:10.1001/jama.2024.22730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。